Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH ADVIL versus MOTRIN IB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH ADVIL versus MOTRIN IB.
JUNIOR STRENGTH ADVIL vs MOTRIN IB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment and elderly.
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal.
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
Category C
Category C
NSAID Analgesic
NSAID Analgesic